Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes

1992 ◽  
Vol 6 (4) ◽  
pp. 364-364
Author(s):  
Ralph D. Harris ◽  
Michael W. Steffes ◽  
Rudolf W. Bilous ◽  
David E. R. Sutherland ◽  
S. Michael Mauer
Keyword(s):  
Insulin Dependent Diabetes ◽  
Glomerular Sclerosis ◽  
Insulin Dependent ◽  
Global Glomerular Sclerosis ◽  
Arteriolar Hyalinosis

scholarly journals Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes

1991 ◽  
Vol 40 (1) ◽  
pp. 107-114 ◽  
Author(s):  
Ralph D. Harris ◽  
Michael W. Steffes ◽  
Rudolf W. Bilous ◽  
David E.R. Sutherland ◽  
S. Michael Mauer
Keyword(s):  
Insulin Dependent Diabetes ◽  
Glomerular Sclerosis ◽  
Insulin Dependent ◽  
Global Glomerular Sclerosis ◽  
Arteriolar Hyalinosis

Factors predicting well-being in adolescents with insulin-dependent diabetes

2002 ◽  
Author(s):  
J. M. Koot ◽  
A. Oldenhave ◽  
G. J. Bruining ◽  
H. J. Aanstoot
Keyword(s):  
Well Being ◽  
Insulin Dependent Diabetes ◽  
Insulin Dependent

Elevated Circulating P-Selectin in Insulin Dependent Diabetes Mellitus

1996 ◽  
Vol 76 (03) ◽  
pp. 328-332 ◽  
Author(s):  
Bernd Jilma ◽  
Peter Fasching ◽  
Christine Ruthner ◽  
Anna Rumplmayr ◽  
Sabine Ruzicka ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Plasma Levels ◽  
Plasma Concentrations ◽  
Insulin Dependent Diabetes Mellitus ◽  
Interquartile Range ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Intergroup Comparison ◽  
Median Plasma ◽  
Insulin Dependent

SummaryBased on findings that showed increased P-selectin expression on platelets and on choroidal microvessels of patients with insulin dependent diabetes mellitus (IDDM), we hypothesized that also plasma concentrations of circulating (c)P-selectin would be increased in these patients.The aim of this study was to compare the plasma levels of cP-selec-tin between non-smoking patients with IDDM, treated with an intensified insulin therapy, and healthy controls. The study design was prospective, cross-sectional and analyst-blinded. Subjects were matched individually for sex, age and body mass index. Plasma levels of cP-selectin and of von Willebrand antigen (vWF-Ag) were determined by enzyme linked immunoassays.Forty-two pairs were available for intergroup comparison. Median plasma concentrations of cP-selectin in patients with IDDM (285 ng/ml; interquartile range: 233-372) were on average 21% higher than those of controls (236 ng/ml; interquartile range: 175-296; p = 0.004). Also, median plasma levels of vWF-Ag were 10% higher in patients (96 U/dl; interquartile range: 82-127) than controls (87 U/dl; interquartile range: 70-104; p = 0.025). There was no correlation between plasma concentrations of cP-selectin and vWF-Ag levels in either group (p ώ0.05).In conclusion, our results of increased cP-selectin levels are in line with increased P-selectin expression on platelets and on choroidal microvessels found in patients with IDDM. In view of the currently developed small molecule inhibitors of cell adhesion molecules, these independent observations together may provide a sound rationale to select P-selectin as a target for treating or preventing IDDM-associated micro- or macrovascular complications.

Platelet Behaviour in Non-Insulin-Dependent Diabetes -Influence of Vascular Complications, Treatment and Metabolic Control

1986 ◽  
Vol 55 (03) ◽  
pp. 361-365 ◽  
Author(s):  
I Peacock ◽  
M Hawkins ◽  
S Heptinstall
Keyword(s):  
Blood Glucose ◽  
Metabolic Control ◽  
Platelet Reactivity ◽  
Platelet Rich Plasma ◽  
Vascular Complications ◽  
Adenosine Diphosphate ◽  
Glycosylated Haemoglobin ◽  
Insulin Dependent Diabetes ◽  
Lipid Levels ◽  
Insulin Dependent

SummaryPlatelet-rich plasma was prepared from 47 patients with noninsulin-dependent diabetes treated with glibenclamide and metformin, and 21 controls. The release of radio-labelled 5-hydroxy-tryptamine in response to aggregating agents (adenosine diphosphate, adrenaline and sodium arachidonate), and the effects on release of a selective thromboxane inhibitor (UK-34787) were investigated. Subsequently, 20 of the diabetic subjects were chosen at random for treatment with insulin; the remainder continued to take tablets. Platelet studies were then repeated, in all patients, after 4 and 6 months.The results showed an association between platelet behaviour and the presence of vascular complications, and were consistent with previous observations of reduced platelet reactivity in patients taking sulphonylureas. There was no correlation of platelet reactivity with blood glucose, glycosylated haemoglobin or lipid levels.

Sign in / Sign up

Export Citation Format

Share Document